3.3 FCGBP is a novel indicator for predicting the progress of
SMPP
Among all the identified proteins which were differentially expressed,
FCGBP was one of the most altered protein with highest fold change. We
then used ELISA to explore its serum expression level between GMPP and
SMPP patients, and tried to investigate the relationship between FCGBP
level and the progress of MPP. On the first day of admission, SMPP
patients showed a higher FCGBP expression tendency (88.22 ± 17.48 ng/mL,
n=16) than that in GMPP patients (50.97 ±10.24 ng/mL, n=7) but did not
reach a statistic significance (Figure 2A, P = 0.057). In the late stage
of disease, SMPP patients exhibited a significantly higher FCGBP
expression than the GMPP patients (Figure 2B, P = 0.0039). During the
disease course, the expression level of serum FCGBP in GMPP group
exhibited a decreased trend while the SMPP group showed the opposite
trend after appropriate treatment (Figure 2C, 2D). Severe sequelae like
BO tend to occur at SMPP patients. These data implicated that FCGBP may
be a promising indicator for predicting the progression of SMPP and
patients who maintain high serum level of FCGBP during treatment may
have a poor prognosis comparing with who decrease.
3.4 Potential TFs regulating
FCGBP expression
The mechanism under the dysregulated expression of FCGBP remains poorly
illuminated. Since TF controls the correct gene expression from DNA to
message RNA, we subjected FCGBP to Cistrome Data Browser toolkit in
order to predict potential TFs, detailed information was described in
method section. Figure 3 shows the identified TFs.